October 01, 2021
The expert medical director at Roche provided detail on results from the phase 2 PASADENA study presented at the 2021 MDS Virtual Congress. [WATCH TIME: 3 minutes]
October 01, 2021
David R. Lynch, MD, PhD, professor of neurology, University of Pennsylvania Perelman School of Medicine, discussed why omaveloxolone’s recent success speaks to the progress made within the FA treatment space.
September 30, 2021
When used for at least 30 days, it was reported that patients with essential tremor reported improvement in tremor power following 54% of sessions.
September 29, 2021
The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the state of care for Friedrich ataxia and omaveloxolone’s potential to become its first approved therapy.
September 27, 2021
Following her presentation at MDS 2021, the PhD candidate in epidemiology at Erasmus University Medical Center discussed highlights from this year’s virtual congress. [WATCH TIME: 2 minutes]
September 27, 2021
The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed whether omaveloxolone’s therapeutic benefit is enough for it to become the first approved therapy for Friedrich ataxia. [WATCH TIME: 2 minutes]
September 26, 2021
The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]
September 26, 2021
Following MDS 2021, we compiled a roundup of some of our discussions with experts in the Parkinson disease and movement disorders space in one convenient location.
September 25, 2021
The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]
September 24, 2021
The director of the UAB Huntington's Disease Clinic offered his insight on a recent assessment of HD genetic testing at HDSA Centers of Excellence, and the associated costs for patients.
The Mobile Stroke Unit Paradigm Shift for EMS: Thomas Topley
American Stroke Association Publishes Updated Guidance for Intracerebral Hemorrhage
FDA Accepts New Drug Application for Intranasal Zavegepant to Treat Acute Migraine
Tackling Neurodegeneration in Multiple Sclerosis: Emily Harrington, MD, PhD